Stock events for electroCore, Inc. (ECOR)
electroCore, Inc.'s stock experienced volatility in the past six months. In October 2025, reimbursement approval was announced for gammaCore™ Sapphire in Belgium. November 2025 saw a significant increase in revenue for the third quarter. The company reported record Q3 2025 net sales of $8.7 million, a 33% year-over-year increase. In January 2026, electroCore expected record revenue of approximately $31.8–$32.0 million for full-year 2025. In February 2026, the stock price was up 16.22% for the month, and year-to-date, the stock was up 72.58% as of February 27, 2026. As of March 6, 2026, the stock price decreased by 8.91% on the last trading day.
Demand Seasonality affecting electroCore, Inc.’s stock price
There is no explicit information detailing seasonality in the demand for electroCore's products and services, but there is data suggesting seasonality in its stock performance. January has shown the highest probability of positive returns for ECOR stock, while March and February have lower probabilities. The company noted typical seasonality related to the filing of their Annual Report on Form 10-K impacting general and administrative expenses in the first quarter of 2025.
Overview of electroCore, Inc.’s business
electroCore, Inc. is a medical technology company specializing in bioelectronic medicine and general wellness, headquartered in Rockaway, New Jersey. The company develops and commercializes non-invasive vagus nerve stimulation (nVNS) therapies. Its major products include gammaCore® and gammaCore Sapphire™ for pain treatment, Truvaga™ and Truvaga 350/Plus for general wellness, TAC-STIM™ for human performance, and Quell® neurostimulator for chronic pain.
ECOR’s Geographic footprint
electroCore, Inc. is based in Basking Ridge and headquartered in Rockaway, New Jersey, United States. The company provides its non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.
ECOR Corporate Image Assessment
electroCore's brand reputation has been positively influenced by the performance improvements of TAC-STIM™ in active-duty United States Air Force Airmen, peer-reviewed studies of gammaCore™, recognition of Truvaga Plus in consumer-focused awards, and reimbursement approval for gammaCore™ Sapphire in Belgium. There is no readily available information indicating specific events that have negatively affected electroCore, Inc.'s brand reputation in the past year.
Ownership
electroCore, Inc. has a mix of institutional and individual owners. As of February 27, 2026, institutional investors own 26.74% of electroCore's stock. Major institutional owners include Vanguard Group Inc., Vanguard Total Stock Market Index Fund Investor Shares (VTSMX), and Tejara Capital Ltd. Significant individual and insider owners include Joseph P. Errico, Merck Global Health Innovation Fund LLC, and James L. L. Tullis.
